| 1 |
35059997 | Engineered T Cells: CAR T Cell Therapy and Beyond. | 2022 Jan |
2 |
| 2 |
35610089 | Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. | 2022 May 21 |
2 |
| 3 |
35619325 | Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. | 2022 May 26 |
2 |
| 4 |
33970454 | Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. | 2021 Jun |
1 |
| 5 |
34125421 | Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. | 2021 Dec |
2 |
| 6 |
32888407 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. | 2020 Sep 19 |
2 |